

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**(Use as many sheets as necessary)**

Sheet 1 of 2

**Complete if Known**

<b>Application Number</b>	09/915,983 — 04/715,983
<b>Filing Date</b>	November 20, 2000
<b>First Named Inventor</b>	Brett P. Monia
<b>Art Unit</b>	1835
<b>Examiner Name</b>	Jane Zara
<b>Attorney Docket Number</b>	ISIS0057-100 (ISPH-0519)

**U.S. PATENT DOCUMENTS**

[illegible]

## FOREIGN PATENT DOCUMENTS


[illegible]

Examiner Signature	<i>[Signature]</i>	Date Considered	8/15/04
-----------------------	--------------------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.**



PTO/SB/08b(08-03)  
Approved for use through 07/31/2006. OMB 0851-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

2

### Complete if Known

Application Number	09/715,983
Filing Date	November 20, 2000
First Named Inventor	Brett P. Monia
Art Unit	1635
Examiner Name	Jane Zara
Attorney Docket Number	ISIS0057-100 (ISPH-0519)

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
83	BB	Skorski et al., "Phosphatidylinositol-3 Kinase Activity Is Regulated By BCR/ABL And Is Required For The Growth Of Philadelphia Chromosome-Positive Cells," <u>Blood</u> , July 15, 1995, Vol. 86, No. 2, pages 726-736.	
	CC	Shigematsu et al., "Role Of Vav Proto-Oncogene Product (Vav) In Erythropoietin-Mediated Cell Proliferation And Phosphatidylinositol 3-Kinase Activity," <u>Journal Of Biological Chemistry</u> , 1997, Vol. 272, No. 22, pages 14334-14340.	
	DD	Agrawal et al., Modified Oligonucleotides As Therapeutic And Diagnostic Agents," <u>Current Opinion In Biotechnology</u> , 1995, Vol. 6, No. 1, pages 12-19.	
	EE	Inukai et al., "p85 $\alpha$ Gene Generates Three Isoforms Of Regulatory Subunit For Phosphatidylinositol 3-Kinase (PI 3-Kinase), p50 $\alpha$ , p55 $\alpha$ , and p85 $\alpha$ , with Different PI 3-Kinase Activity Elevating Responses To Insulin," <u>The Journal Of Biological Chemistry</u> , March 21, 1997, pages 7873-7882.	
	FF	European Search Report Dated May 18, 2004 for Application No. 00957982.2	

Examiner  
Signature

83

Date  
Considered

8/15/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.